Losartan and Hypofractionated Radiation Therapy after Chemotherapy for the Treatment of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer, the SHAPER Study

Inclusion Criteria

• Male or female subject aged >= 18 years
• Histologically confirmed pancreatic ductal adenocarcinoma
• Borderline resectable or locally advanced unresectable pancreas cancer as defined by the National Comprehensive Cancer Network (NCCN) and determined by a pancreatic surgeon prior to therapy. This can be confirmed by the surgeon’s documentation in the electronic medical record, by a treatment planning conference note, or by the signature of a pancreatic surgeon
• At least one infusion of fluorouracil, irinotecan, leucovorin, oxaliplatin (FOLFIRINOX) or gemcitabine based chemotherapy must have been attempted
• No more than 6 months of chemotherapy. Each completed cycle of FOLFIRINOX will be counted as 0.5 months. Each completed cycle of gemcitabine based chemotherapy will be counted as 1 month. If a partial cycle of chemotherapy is given, that partial cycle will be counted proportional to the amount given. e.g. if one of three planned infusions of gemcitabine based chemotherapy is given, it will be counted as 1/3 month
• Enrollment must occur within 90 days of day 1 of the last infusion given of chemotherapy. Patients who have primary tumor or regional lymph node progression on chemotherapy or prior to enrollment are eligible if no distant metastases are identified on the screening imaging assessment
• Eastern Cooperative Oncology Group (ECOG) performance status =< 1
• Absolute neutrophil count (ANC) >= 1500/uL
• Platelets >= 100k/uL
• Total Bilirubin =< 2.0 mg/dL
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)
• Serum creatinine < 1.25 mg/dL
• Serum potassium < 5.0 mmol/L
• Negative serum or urine pregnancy test at screening for women of childbearing potential
• Highly effective contraception for both male and female subjects throughout the study and for at least 12 months after last study treatment administration if the risk of conception exists
• Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from toxicities related to any prior treatments, unless AEs are clinically nonsignificant and/or stable on supportive therapy
• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines

Exclusion Criteria

• Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen of this trial
• Distant metastases. Regional lymphatic disease is acceptable
• Prior radiation therapy or definitive resection for pancreatic cancer
• Uncontrolled gastric or duodenal ulcer disease within 28 days of registration
• Chronic cough, defined 30% of days over 3 months with active symptoms at enrollment or over 12 months with last active symptoms occurring 6 months prior to enrollment
• Symptomatic hypotension (blood pressure < 90 systolic or < 60 diastolic at screening vital sign assessment) that has the potential to interfere with the patient’s safety or ability to complete protocol treatment, at the discretion of the treating investigator
• Patients taking > 50 mg losartan QD who, at the discretion of the treating investigator, cannot be safely reduced to the protocol defined regimen
• Patients taking an angiotensin II receptor blocker or an angiotensin-converting enzyme inhibitor who, at the discretion of the treating investigator, cannot be safely discontinued prior to day 1 dosing
• Patients taking direct renin-angiotensin system inhibitors including aliskiren (Rasilez)
• Prior allergy to an angiotensin II receptor blocker
• Concurrent use of direct renin inhibitor including aliskiren (Rasilez)
• Patients with known history of: * Heart failure. Patients with heart failure, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Patients with a prior history of treatment with cardiotoxic agents should be evaluated for heart failure prior to enrollment at the discretion of the treating investigator * Solitary kidney, renal artery stenosis, or chronic renal failure
• Human immunodeficiency virus (HIV)-infected patients who are not on effective anti-retroviral therapy or have a detectable viral load within 6 months of trial entry
• Patients with known evidence of chronic hepatitis B virus (HBV) infection and a detectable HBV viral load
• Patients with a history of hepatitis C virus (HCV) infection who have not been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
• Subject is currently enrolled on another investigational treatment study for pancreas cancer